Rana McKay is an inspiration! Charting her journey from Lebanon to the US, her passion for oncology motivated by her Mum’s experience of breast cancer, her determination to improve outcomes of patients with kidney cancer. She receives the Chris Wood Award Kidney Cancer

Mad respect ✊🏻💚🧡

🏆Congratulations Dr. Bernard Escudier Gustave Roussy on the #IKCSEU24 Nicholas J Vogelzang Humanitarian Award! Thank you for remembering fellow champions of #kidneycancer care (we miss Nick and Chris 🧡). Wonderful intro from KCA Board member Laurence Albiges.

Thank you Rana McKay for a heartfelt talk about what led you to be the incredible #kidneycancer doctor you are. Well-deserved recipient of the Chris G Wood Rising Star Award. With intro from KCA Board Chair B.C. Leibovich MD. #IKCSEU24

Congratulations to our dear friend Rana for receiving the prestigious 2024 Christopher G. Wood Rising Star Award at the IKCS Europe, a well-earned recognition of her exceptional work in kidney cancer research! Your dedication and hard work have truly paid off. Cheers to your

Powerful testimonies from two young women with metastatic translocation kidney cancer. Thank you for reminding us of all the work we still need to do for #RareCancers #IKCSEU24 Kidney Cancer ❤️

Daniel Heng with an outstanding 'oncologists perspective' on RCC classification (including a discussion of Renee Maria Saliby's recent Cancer Cell paper). #IKCSEU24 Kidney Cancer

Daniel Heng with a thorough and systemic overview of the biology and treatment outcomes in translocation RCC. Some initial excellent work from Ziad Bakouny, MD, MSc Srinivas Viswanathan highlight, but clear that additional work is needed in this disease. #IKCSEU24 Kidney Cancer

Great to be in Sitges! KN564 expectations for subsequent therapy numbers in adjuvant #kidneycancer pembrolizumab should be tempered because it is a moving target in how we capture it Tom Powles #IKCS2024 . So I think KN564 post therapy numbers are reasonable.

Excited to share our work The Oncologist co-led by Georges Gebrael and mentored by Toni Choueiri, MD Daniel Heng

While smoking cessation is crucial 🚭, smoking status does not independently affect outcomes in pts w/ #mRCC treated w/ 1L ICI

OncoAlert UroToday.com
tinyurl.com/mv44nycci

Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembro in this setting NEJM Toni Choueiri, MD nejm.org/doi/full/10.10…

Tips on talking to children about a cancer diagnosis - Dana-Farber's Toni Choueiri, MD, (@DrChoueiri) and Max McMahon, LICSW, discuss in TIME having the conversations and how diagnosis and treatment can impact the entire family.

CC: Dana-Farber_GU

ms.spr.ly/6010c460C

Serial ctDNA testing, a better risk-stratification tool? Does adjuvant NIVO have more benefits than PBO in ITT & PD-L1 ≥ 1 populations?
More IMvigor011 & CheckMate 274 updates at #EAU24 Game-Changing Session lectures by Tom Powles & Matt Galsky

👉 eaucongress.uroweb.org/game-changing-…

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

TDXD received FDA accelerated approval in HER2 IHC 3+ treatment refractory tumors. While HER 1-3+ is common in UC, 3+ is <25% (RR-50% n=16). New treatments are welcome. Ongoing testing needed. This seems an ambitious accelerated approval in UC #EAU24 . fda.gov/drugs/resource…

❓What's the role of teratoma in prognosis of patients with non-seminomatous germ cell cancer! An IGCCCG consortium study;
🧍6792 patients with metastatic testicular NSGCT, 47% had teratoma in th primary, and 53% did not!
↘️ Presence of teratoma in primary tissue was associated

The Arthur J.E. Child Comprehensive Cancer Centre is more than just a building. It is an ambitious dream, a beacon of hope.⁠ In two short days, we're sharing a BIG announcement that will turn this dream into a reality.
⁠
Join us on April 1 to help us #OWNCANCER !

NATALEE phase 3 trial... deserves a sensitivity analyis !

remember the monarchE trial (adjuvant abemaciclib for 2⃣ years)

--> now we have NATALEE with adjuvant ribociclib for 3⃣ years ‼️

iDFS benefit !
... but let's have a closer look !
1/🧵

#USCAP2024 kicks off with the presentation of the State of the Academy and USCAP honors 🥳
Cannot wait for the tremendous learning opportunities !!

📢Thrilled to announce that TIDE-A trial is finally out on European Urology! Thanks to all coauthors for supporting 1️⃣st trial of TKI interruption in IO combo for #mRCC . sciencedirect.com/science/articl… Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Brian Rini, MD OncoAlert Università Cattolica Kidney Cancer IKCC Kidney Cancer